Listing Category
Description
A Phase 2b/3, Randomized, Double-Blind, Placebo- Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)